Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) have received a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, four have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $21.00.

A number of analysts have recently commented on the stock. Wall Street Zen upgraded shares of Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, October 18th. Craig Hallum reissued a “buy” rating and set a $22.00 price target on shares of Phathom Pharmaceuticals in a research report on Friday, October 31st. Raymond James Financial assumed coverage on shares of Phathom Pharmaceuticals in a research note on Thursday, December 11th. They set a “strong-buy” rating and a $28.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Barclays started coverage on shares of Phathom Pharmaceuticals in a report on Monday, December 8th. They set an “equal weight” rating and a $16.00 target price for the company.

Phathom Pharmaceuticals Stock Performance

PHAT stock opened at $15.60 on Friday. Phathom Pharmaceuticals has a fifty-two week low of $2.21 and a fifty-two week high of $18.31. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -4.08 and a beta of 0.48. The business’s 50 day moving average price is $15.30 and its two-hundred day moving average price is $12.40.

Phathom Pharmaceuticals (NASDAQ:PHAT) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.15. The firm had revenue of $49.50 million for the quarter, compared to the consensus estimate of $47.03 million. Sell-side analysts forecast that Phathom Pharmaceuticals will post -4.78 earnings per share for the current year.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its holdings in shares of Phathom Pharmaceuticals by 0.8% during the second quarter. JPMorgan Chase & Co. now owns 138,516 shares of the company’s stock valued at $1,328,000 after acquiring an additional 1,123 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in Phathom Pharmaceuticals by 39.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,311 shares of the company’s stock valued at $41,000 after purchasing an additional 1,216 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Phathom Pharmaceuticals by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,826 shares of the company’s stock valued at $152,000 after purchasing an additional 1,364 shares during the last quarter. Jones Financial Companies Lllp increased its stake in Phathom Pharmaceuticals by 442.6% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company’s stock valued at $30,000 after purchasing an additional 2,058 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Phathom Pharmaceuticals by 58.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,710 shares of the company’s stock valued at $55,000 after purchasing an additional 2,102 shares in the last quarter. 99.01% of the stock is owned by institutional investors.

Key Headlines Impacting Phathom Pharmaceuticals

Here are the key news stories impacting Phathom Pharmaceuticals this week:

• Positive Sentiment: Updated revenue guidance for Q4 2025 and full-year 2025 came in marginally above consensus (Q4: $57.0M–$58.0M vs. $56.7M consensus; FY: $174.5M–$175.5M vs. $174.2M consensus), suggesting top-line performance was roughly in line-to-slightly-better-than expected — a modest positive for revenue growth expectations.
• Neutral Sentiment: Phathom released preliminary, unaudited fourth-quarter and full-year 2025 financial results (details in the company release); investors will watch the final audited figures and any accompanying commentary for margin, cash burn, and product performance signals. Preliminary Fourth-Quarter and Full-Year 2025 Financial Results
• Negative Sentiment: Phathom priced an underwritten public offering totaling roughly $130 million, consisting of 6,875,000 common shares and pre-funded warrants to purchase 1,250,078 shares — a clear near-term dilution overhang that typically pressures the share price. Pricing of $130 Million Public Offering
• Negative Sentiment: The company had earlier announced the proposed offering, which triggered initial selling; media coverage highlighted the offering as the main reason for today’s decline, amplifying downward momentum. Proposed Public Offering
• Negative Sentiment: Market commentary and news outlets explicitly tied the share drop to the planned/priced offering (coverage from Investing.com, MarketWatch, and AAII), which likely increased selling pressure as investors priced in dilution risk. Investing.com: Stock Falls on Planned Public Offering MarketWatch: Shares Fall on Public Offering AAII: Why PHAT Is Down

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.